ArticleCureus2025
Overall Diagnostic Efficiency of a Noninvasive Diagnostic Strategy Aimed at Early Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Noninvasive methods for assessing liver fibrosis are increasingly important for early detection of advanced liver fibrosis (ALF), particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to evaluate the overall diagnostic ability and efficiency (ODAE) of noninvasive diagnostic strategies incorporating imaging tests and to identify optimal test combinations for early ALF detection. Methods We conducted a simulation of 10,000 MASLD patients, assuming an ALF prevalence of 15%. Two diagnostic strategies were evaluated. Strategy one (two-step): patients positive on the Fibrosis-4 (Fib-4) index (cutoff ≥1.3) underwent magnetic resonance elastography (MRE), vibration-controlled transient elastography (VCTE), or shear wave elastography (SWE). Strategy two (three-step): Fib-4-positive patients underwent additional serum fibrosis marker testing - enhanced liver fibrosis score, Mac-2-binding protein glycosylation isomer, or type IV collagen 7S - followed by imaging if positive. Diagnostic performance, including net sensitivity, specificity, predictive values, and accuracy, was estimated using decision tree analysis based on published parameters. Results Fib-4 identified 5,742 positive cases. Strategy one achieved high accuracy (0.90-0.93); combining Fib-4 with MRE or SWE as a secondary test demonstrated good and comparable ODAE. Strategy two further improved positive predictive value and reduced false positives compared with strategy one. Conclusions Combining Fib-4 with MRE or SWE provides comparable and efficient diagnostic performance for early detection of ALF. Adding serum fibrosis markers as an intermediate step may further reduce false positives and enhance diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.